Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes

Next Previous
Trial Profile

A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk

Most Recent Events

  • 08 Oct 2013 Planned number of patients changed from 177 to 252 as reported by European Clinical Trials Database record.
  • 20 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD 2010).
  • 28 Jun 2010 Results were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top